Exploration of Endocrine and Metabolic Diseases

Article Recommendation: Epigenetics in etiopathology of hyperprolactinemia Author: Amanpreet Kaur Kalsi*, Ashutosh Halder*, Manish Jain, Jai Bhagwan Sharma Journal: Explorations in Endocrine and Metabolic Diseases DOI: https://lnkd.in/gZVNFJeZ 🔍 Did you know? Epigenetic alterations may play a critical role in hyperprolactinemia—a condition affecting millions globally, often linked to pituitary tumors and antipsychotic use. 🌟 Key Findings: ✅ DNA Methylation Shifts: Patients with hyperprolactinemia (prolactin >100 ng/mL) showed significant global DNA hypermethylation compared to controls. ✅ Drug & Disease Interplay: 66.67% of hypomethylated cases were on antipsychotics, highlighting epigenetic mechanisms in medication-related endocrine disruption. ✅ Genomic Clues: Genome-wide analysis identified MHC-related pathways and cellular components as potential epigenetic drivers of hyperprolactinemia. 🌐 Why It Matters: This study bridges basic science and clinical practice, offering novel targets for precision therapies in endocrine disorders. With hyperprolactinemia prevalence rising—especially in populations on antipsychotics—these findings could reshape diagnostic and treatment strategies. 📚 Read the Full Article 👉 https://lnkd.in/gJfJwsZU #Epigenetics #Endocrinology #MetabolicDisease #PituitaryHealth #MentalHealth

📢 Article Recommendation: A brief approach to hypertension in type 2 diabetes mellitus Author: Yilmaz Gunes (Bolu Abant Izzet Baysal University, Turkiye) Journal: Explorations in Endocrine and Metabolic Diseases DOI: https://lnkd.in/gip93w98 Hypertension (HT) and type 2 diabetes (T2DM) coexist in >75% of patients, driving multiplicative cardiovascular and renal risks. This concise review offers actionable strategies to optimize outcomes: 🔑 Key Highlights: Targets: Aim for <130/80 mmHg (if tolerated), balancing benefits of intensive control with risks in frail patients. First-Line Therapy: ACEIs/ARBs + CCBs/thiazides – proven to reduce mortality and microvascular complications. Resistant HT? Add MRAs (e.g., spironolactone) or leverage SGLT2i/GLP-1RAs for dual cardiorenal protection. Lifestyle Matters: DASH diet, weight loss, and exercise amplify treatment efficacy. 🚀 Future Focus: Emerging agents (zilebesiran, aprocitentan) and fixed-dose combos promise better adherence and BP control. 👉 Read Now: https://lnkd.in/gc97Jyx2 👉 Download PDF: https://lnkd.in/gvKzHsr6 #Hypertension #DiabetesCare #Cardiology #ClinicalGuidelines #Endocrinology #MedicalResearch

📢 Special Issue Call for Papers: "Regulators of Glucose Homeostasis, Lipid Metabolism and Energy Balance" 📅 Submission Deadline: July 3, 2025 | Submit Now: https://lnkd.in/gSg9MyaH 👨🔬 Guest Editor: Prof. Nikolaos Perakakis (Technische Universität Dresden, Germany) Metabolic diseases are a global health priority, driven by disruptions in energy balance, glucose regulation, and lipid metabolism. This special issue aims to explore the biomolecules and mechanisms that govern metabolic health, from novel biomarkers to therapeutic targets. We look forward to your submissions! So far, two articles have been published: 1️⃣ Four hepatic steatosis indices in predicting quantitative computed tomography-based metabolic dysfunction-associated fatty liver disease 🔍 Evaluates the diagnostic performance of FLI, HSI, FSI, and ZJU index for MAFLD using advanced imaging techniques. Read Full Article: https://lnkd.in/g4Njza9r 2️⃣ Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques 💊 Explores FXR as a groundbreaking therapeutic target for MASLD and its implications for metabolic disorders. Read Full Article: https://lnkd.in/gEvTr6uz 📚 Learn more about the special issue: https://lnkd.in/gETSnXB8 🎯 Submit now: https://lnkd.in/gSg9MyaH ✉️ Contact us: [email protected] Don't miss this exciting opportunity to contribute to this groundbreaking collection and be part of the advancement in the field of metabolic health research! 🌍🔬 #MetabolicHealth #Diabetes #NAFLD #NASH #Lipidomics #FXRagonists #SpecialIssue

🌟 New Publication Alert: GRα as Master Regulator of Homeostasis in Critical Illness We are pleased to announce the publication of a groundbreaking open-access review in Exploration of Endocrine and Metabolic Diseases: 📌 Title: Glucocorticoid receptor alpha: origins and functions of the master regulator of homeostatic corrections in health and critical illness 📌 Author: Gianfranco Umberto Meduri 📌 DOI: https://lnkd.in/g4-2KqBK The glucocorticoid receptor alpha (GRα) is no ordinary player. As a cornerstone of the ancient glucocorticoid signaling system, it's been pivotal for vertebrate survival for over 450 million years. 🦕 It orchestrates a symphony of functions, from fertility and fetal development to how our bodies manage metabolism, immune responses, and stress. In the context of critical illness, GRα takes center stage. It expertly navigates the body through three crucial phases: 🔹 Priming Phase: Think of it as the body's early-warning system. GRα springs into action, activating immune responses and shoring up energy reserves. 🔹 Modulatory Phase: Here, it delicately fine-tunes inflammation, ensuring our bodies don't over-react, while also maintaining the integrity of our vascular system. 🔹 Restorative Phase: The final act in the recovery play, GRα helps resolve inflammation and kick-starts the all-important process of tissue repair. The review also dives deep into: ✅ GRα's co-evolution with mitochondria and immune systems ✅ The hidden role of micronutrients (vitamins C/D, thiamine) in boosting GRα function ✅ Why depleted nutrient reserves in ICU patients demand urgent clinical attention Access the full article here: https://lnkd.in/g4-2KqBK #GlucocorticoidReceptor #CriticalCare #Homeostasis #SepsisResearch #ICURehabilitation #Endocrinology #Metabolism

Article Recommendation: Hypoparathyroidism, deafness and renal dysplasia syndrome with bilateral cataract and bicornuate uterus caused by a de novo GATA3 mutation 📝 Authors: Rajesh Chetiwal, Amit Kumar*, Shweta Tanwar, Priyank Rastogi DOI: https://lnkd.in/gtSsSnF9 This case reports HDR syndrome (Hypoparathyroidism, Deafness, and Renal Dysplasia) caused by a de novo mutation (c.144delG) in the GATA3 gene. The patient, a 22-year-old female, presented with the classic triad (hypocalcemia, bilateral sensorineural deafness, and renal cysts), and for the first time, bilateral cataract and bicornuate uterus were discovered, expanding the clinical phenotypic spectrum of this syndrome. 🔍 Main Content 1️⃣ Clinical Features: • Hypocalcemia (manifested as cramps, seizures), low PTH, renal dysplasia (bilateral cysts), and deafness. • New phenotypes: Bilateral cataract (possibly related to chronic hypocalcemia) and bicornuate uterus (suggesting the role of GATA3 in the development of the reproductive system). 2️⃣ Genetic Mechanism: • A frameshift mutation (c.144delG) in exon 3 of the GATA3 gene was detected, resulting in a truncated zinc - finger domain and affecting embryonic development. • The mutation was de novo (not carried by parents or siblings), supporting the existence of sporadic HDR cases. 3️⃣ Diagnosis and Treatment Implications: • Multidisciplinary management (calcium/vitamin D replacement, cataract surgery, renal function monitoring) significantly improved the prognosis. 🔗 Read the full case report: https://lnkd.in/gtbUEMpA #HDRSyndrome #GeneticDisorders #RareDiseases #Endocrinology #PrecisionMedicine

🌟 New Article Alert! Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques Authors: Pirangi Srikanth, Khaja Moinuddin Shaik, Vijay Patibandla, Deepak Kumar, Sukhendu Nandi* Explor Endocr Metab Dis. 2025 | DOI: https://lnkd.in/gd2tg5c2 🔥 The Global Health Crisis You Can't Ignore: Over 30% of the global population is now affected by metabolic dysfunction-associated steatotic liver disease (MASLD)—a silent epidemic fueled by obesity and diabetes. Without action, prevalence could skyrocket to 55% by 2040. FXR agonists are emerging as a potential game-changer in the fight against MASLD. FXR not only regulates lipid metabolism but also combats inflammation and insulin resistance. With only one FDA-approved drug, resmetirom, currently available, exploring FXR agonists opens new avenues for innovative treatments that could revolutionize patient care. 🔬 Key Insights: • Lipidomics Unlocked: Advanced analytical techniques reveal critical lipid alterations (e.g., triglycerides, fatty acids) driving MASLD progression. • Mechanistic Mastery: FXR agonists restore balance in lipid uptake, de novo lipogenesis, and oxidation—halting disease progression. • Clinical Promise: Early trials show FXR agonists improve liver histology and metabolic parameters, paving the way for combo therapies with fewer side effects. 👉 Read the Full Review: https://lnkd.in/gEvTr6uz 👉 Join the Conversation on metabolic liver diseases—let's collaborate to tackle this global challenge! #MASLD #LiverHealth #FXR #MetabolicSyndrome #Lipidomics #DrugDiscovery #HealthcareInnovation

📢 Call for Papers | Role of Dysregulated Cytokine Signaling Pathways in Metabolic Disease 👨 Guest Editor: Prof. Alister C. Ward from Deakin University, Australia Metabolism represents a complex and highly regulated system that ensures that cells, tissues and body systems function effectively and efficiently in a myriad of situations. This central plank of homeostasis is co-ordinated by multiple layers of control, but is strongly impacted by cytokine receptor signaling. Furthermore, disruption of these signals through environmental and genetic factors is associated with a range of metabolic diseases. This Special Issue, which is entitled 'Role of dysregulated cytokine signaling pathways in metabolic disease' will focus on the central role played by alterbed cytokine signaling in the pathogenic disruption of metabolism. We look forward to your submissions. 📚 Learn more about the special issue: https://lnkd.in/gM8HqqyT 🎯 Submit now: https://lnkd.in/gSg9MyaH ✉️ Contact us: [email protected] 🚀 Join the Quest! From bench to bedside, your research can redefine how we diagnose and treat metabolic disorders. Let's bridge molecular mechanisms to clinical innovation! #Metabolism #CytokineSignaling #JAKSTAT #MetabolicDisease #Immunometabolism

📢 Article Recommendation: Adult-onset testosterone deficiency: the usefulness of hormone replacement in reducing mortality in men with this common age-related condition Authors: Amar Mann, Richard C. Strange, Geoffrey Hackett, Carola König, and Sudarshan Ramachandran* DOI: https://lnkd.in/eeYyt_Tt 🌟 Key Highlights 🌟 📈 Adult-onset testosterone deficiency (TD) is prevalent, especially in men over 50, and even more so in those with type 2 diabetes (T2DM). Low serum testosterone levels in this population are linked to increased mortality risk. 📈 Through an in-depth review of literature and analysis of the BLAST study cohort, researchers found that testosterone therapy (TTh) significantly reduces mortality, particularly in men with T2DM. Notably, the survival benefit of TTh was strongest in men over the median age of 65.89 years. 📈 Mechanistic insights: Adult-onset TD is a heterogeneous condition. TTh may lower all-cause mortality by improving associated phenotypes such as metabolic syndrome, hyperglycemia, hypertension, dyslipidemia, low hematocrit, sex hormone-binding globulin (SHBG) levels, and erectile dysfunction. 📈 Clinical considerations: Variations in testosterone assay methodologies, the role of free testosterone measurement, selection of testosterone formulations, and CAG repeat polymorphisms in the androgen receptor gene (linked to treatment response) are critical for optimizing management. 📖 The full article is OPEN ACCESS: https://lnkd.in/gDrm3VSP 📊 Special Issue Alert: This article is part of the special issue "The Fountain of Youth: Decoding the Hormonal Regulation of Aging" —submit your research! 🔗 https://lnkd.in/giR7ZX6E #MensHealth #TestosteroneTherapy #DiabetesCare #AgingResearch

🌟 Article Recommendation: Whole-exome sequencing uncovered 3-hydroxy-3-methylglutaryl-CoA lyase deficiency as the cause of lethal metabolic crisis in a Vietnamese infant 📝 Authors: Hong Thu Nguyen-Huu, Khanh Linh Nguyen, Phuong Nhung Vu, Hai Ha Nguyen* Open access paper 👉 https://lnkd.in/gg5kP8T7 🎯 Abstract: Metabolic disorders are due to a deficiency of enzymes, which can severely impact health or cause serious complications without treatment. This study aimed to identify the molecular causes of an infant death who had been hospitalized with complicated health problems and metabolism syndrome. Whole-exome sequencing (WES) was used to screen pathogenic variants in the patient's genome, followed by examination of variants segregation in her parents. The WES analysis identified two homozygous variants, c.[614C>G; 649A>G] in the HMGCL gene of the patient. These two variants co-locate within the exon 7 of the HMGCL gene, resulting in 2 amino acid substitutions, p.[T205S; M217V], in the conservative region of enzyme protein. Sanger sequencing showed that the patient's unaffected mother and father carried one mutant allele of the HMGCL gene containing two c.[614C>G; 649A>G] variants. The HMGCL gene encodes the 3-hydroxy-3-methylglutaryl-CoA lyase enzyme, which is critical in the ketogenic pathway. The deficiency of this enzyme was reported to be a life-threatening illness in the neonatal period, and two variants detected in this study were also found in a Japanese patient with sudden, unexpected death in infancy. The frequency of these two variants in the Vietnamese in-hour database and their further functional analysis were also reported in this study. The results of this study have explored the molecular etiology that causes the severe, deadly condition of the patient and provide an understanding of the risk of disease in her family. 🔍 Figure 3 from the article illustrates the mutation spectrum across the HMGCL gene, highlighting the prevalence and types of mutations, including a focus on exon 7's potential role in enzyme dysfunction. 📖 Dive Deeper: Explore the full structural biology insights and population health implications in our open-access article: https://lnkd.in/gg5kP8T7 #MetabolicDisorders #GeneticsInAction #NewbornScreening #PrecisionMedicine #RareDiseases #VietnamResearch

🚀 New Special Issue Call for Papers: Innovative Strategies for Diabetes & Metabolic Disorders We are pleased to announce that our latest Special Issue, "Innovative Strategies for Diabetes and Metabolic Disorders: Current and Future Directions," is now open for submissions! 📅 Submission Deadline: September 20, 2025 🔗 Submit your manuscript: https://lnkd.in/gSg9MyaH 📚 Learn more about the Special issue: https://lnkd.in/gfTR5AZA With diabetes, obesity, and related metabolic disorders escalating globally, there is an urgent demand for transformative solutions. This issue aims to highlight innovative and groundbreaking research—from novel drug targets and biomarkers to advanced therapies such as peptide diagnostics, dual agonists, and precision medicine approaches. Key Themes Include: 🔹 Molecular mechanisms of metabolic dysfunction (fundamental studies) 🔹 Innovative therapeutic agents (e.g., novel drug targets, advanced drug delivery systems) 🔹 Diagnostic biomarkers and omics technologies for early disease detection 🔹 Translational research evaluating safety/efficacy of emerging therapies 🔹 Personalized management strategies and risk stratification approaches 🔹 Interplay between metabolic pathways and targeted interventions 🔹 Challenges in addressing intertwined conditions Meet the Guest Editors: 👨🔬 Dr. Dawood Khan (Ulster University, United Kingdom) Expertise: Diabetes, obesity, incretin therapies, fertility-metabolism interplay 👨🔬 Prof. Victor Gault (Ulster University, United Kingdom) Expertise: Incretin hormones, drug discovery, metabolic disorder therapeutics Call to Action 📢 Contribute Now: Leverage zero APC fees and open access dissemination. 🔗 Engage the Community: Tag researchers in #DiabetesCare, #MetabolicEngineering, or #TranslationalScience 📩 Contact Us: [email protected] Join us in advancing the field and making a real difference in the lives of those affected by diabetes and metabolic disorders. Your research can be part of the solution! #DiabetesResearch #MetabolicDisorders #Obesity #PeptideTherapeutics #TranslationalMedicine #HealthcareInnovation #CallForPapers #ExplorationEndocrineMetabolicDiseases